Transgender Medicine AND Hormone Therapy

The answer first

Transgender Medicine AND Hormone Therapy is managed with an answer-first physician approach: recognise the pattern, exclude dangerous differentials, choose investigations that change action, and deliver a sequenced management plan that accounts for multimorbidity. [1] [2]

The FRACP candidate must be able to open a long-case presentation, defend thresholds, and answer DWE vignettes without hedging. Lead with the decision, then the evidence and the trap. [1]

Clinical spectrum and red flags

Presentations range from incidental or outpatient findings to emergency decompensation. Always ask what would make this urgent today — airway, perfusion, neurological threat, metabolic crisis, infection, or bleeding. [1] [2]

Red flags force same-day action rather than elective pathways. Document them explicitly in the plan. [1]

Classification that changes management

Classify by acuity, mechanism, severity and care setting. A useful classification changes investigation choice, initial therapy, disposition or specialist referral — otherwise it is taxonomy without purpose. [1] [2]

Pathophysiology linked to bedside decisions

Mechanism matters when it predicts treatment response, complications or monitoring. Teach pathophysiology as a bridge to action, not as isolated basic science. [1] [2] [3]

Differentials and discrimination

Build a short differential that includes the common, the dangerous and the commonly missed. For each alternative, name one history clue, one examination clue and one investigation that discriminates. [1] [2]

Investigations

Order tests that change management. State what is required now, what can wait, and what is low-value or harmful. Interpret results in clinical context rather than in isolation. [1] [2]

Management — immediate then definitive

1. Stabilise threats to life and organ function. [1]
2. Start disease-specific therapy once the working diagnosis is secure enough to act. [1] [2]
3. Address complications, drug interactions and monitoring. [1] [2]
4. Plan disposition, follow-up intensity and patient education with safety-net advice. [1]

Complications and prognosis

Anticipate early and late complications. Prognosis depends on severity at presentation, speed of effective therapy, comorbidity and adherence to secondary prevention or disease-modifying treatment. [1] [2]

Special populations and multimorbidity

Adjust for pregnancy potential, frailty, CKD, liver disease, immunosuppression and polypharmacy. In older adults, goals-of-care and treatment burden can change the preferred plan even when disease-directed options remain available. [1] [2]

DCE long-case angles

Open with a one-sentence synthesis, then a prioritised problem list, then an integrated plan covering investigations, treatment, prevention and communication. Link Transgender Medicine AND Hormone Therapy to cardiovascular risk, infection risk, medications and social context where relevant. [1] [2]

DCE short-case angles

Be prepared to demonstrate or discuss focused examination findings, interpret a key investigation, and counsel on risks, benefits and follow-up in plain language. [1]

Exam traps

1. Delaying urgent care because the presentation looks "stable enough". [1]
2. Treating a syndrome label without confirming mechanism. [1] [2]
3. Forgetting drug interactions and organ-function dosing. [1] [2]
4. Omitting safety-net advice and follow-up ownership. [1]
5. Quoting thresholds without knowing the source trial or guideline. [1] [2] [3]

References

1. [1]Hastie E, Khetan P, LaMere SA, George AF, et al. The HIV Reservoir and Immune Landscape Across the Life Course of Women: Implications for Cure Strategies Am J Reprod Immunol, 2026.PMID 42461585
2. [2]Yoon JW, Kim G, Lee ES, Lee SY, et al. Cervical cancer screening and HPV vaccination among assigned female at birth transgender and gender-diverse individuals in South Korea: findings from the KITE cohort BMC Public Health, 2026.PMID 42437894
3. [3]Thomas TA, Winston-McPherson GN, Amarillo I, Berry AD, et al. ADLM Guidance Document on Incorporating Gender Diversity in Pathology and Laboratory Medicine J Appl Lab Med, 2026.PMID 42383916
4. [4]Hastie E, Bortner A, Wagner GA, Blumenthal J Gender-Affirming Medical Treatment of Transgender and Gender-Diverse Individuals Obstet Gynecol Clin North Am, 2026.PMID 42236065
5. [5]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
6. [6]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922
7. [7]Hajiaqaei M, Mohammadi A Transcranial random noise stimulation (tRNS) over the left dorsolateral prefrontal cortex ameliorates emotion dysregulation and executive function: a single-blind, randomized, sham-controlled clinical trial BMC Psychol, 2026.PMID 42469906
8. [8]Weiß A, Haussmann J, Goeckenjan M Establishing a Transgender Outpatient Clinic Within the Gynaecology Department: a Retrospective Analysis of the First Few Years Geburtshilfe Frauenheilkd, 2026.PMID 42459842
9. [9]Tosi M, Lisso F, Maruca F, Pujia C, et al. Nutritional Monitoring During Gender-Affirming Hormone Therapy: Body Composition and Metabolic Implications Nutrients, 2026.PMID 42356353
10. [10]Mudupula Vemula SS, Shah N, Atti L, Akanbi M, et al. Venous Thromboembolism Risk in Transgender Women on Feminizing Hormone Therapy: A Narrative Review of Formulation-Specific Risks, Management Strategies, and Evidence Gaps Cureus, 2026.PMID 42328257
11. [11]Muradov I, Uysal S, Kocaman BB, Soltanova L, et al. Cross-sectional comparison of cardiometabolic markers in transgender men receiving gender-affirming hormone therapy Endocrine, 2026.PMID 42430065
12. [12]Fiala L, Kestlerova D, Nespor J, Lenz J Early biopsychological changes during masculinizing gender-affirming hormone therapy in AFAB transgender individuals: a 4-month prospective study Front Psychiatry, 2026.PMID 42389397